174 related articles for article (PubMed ID: 36718027)
21. Comparison of the Formula of PSA, Age, Prostate Volume and Race Versus PSA Density and the Detection of Primary Malignant Circulating Prostate Cells in Predicting a Positive Initial Prostate Biopsy in Chilean Men with Suspicion of Prostate Cancer.
Murray NP; Reyes E; Fuentealba C; Orellana N; Morales F; Jacob O
Asian Pac J Cancer Prev; 2015; 16(13):5365-70. PubMed ID: 26225679
[TBL] [Abstract][Full Text] [Related]
22. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer.
Gomella LG; Raj GV; Moreno JG
J Urol; 1997 Aug; 158(2):326-37. PubMed ID: 9224297
[TBL] [Abstract][Full Text] [Related]
23. Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms.
Chalfin HJ; Glavaris SA; Malihi PD; Sperger JM; Gorin MA; Lu C; Goodwin CR; Chen Y; Caruso EA; Dumpit R; Kuhn P; Lang JM; Nelson PS; Luo J; Pienta KJ
J Urol; 2018 Jun; 199(6):1494-1501. PubMed ID: 29339080
[TBL] [Abstract][Full Text] [Related]
24. Ad5/35E1aPSESE4: A novel approach to marking circulating prostate tumor cells with a replication competent adenovirus controlled by PSA/PSMA transcription regulatory elements.
Hwang JE; Joung JY; Shin SP; Choi MK; Kim JE; Kim YH; Park WS; Lee SJ; Lee KH
Cancer Lett; 2016 Mar; 372(1):57-64. PubMed ID: 26723876
[TBL] [Abstract][Full Text] [Related]
25. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
26. A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions.
Zielie PJ; Mobley JA; Ebb RG; Jiang Z; Blute RD; Ho SM
J Urol; 2004 Sep; 172(3):1130-3. PubMed ID: 15311056
[TBL] [Abstract][Full Text] [Related]
27. Identifying cancer origin using circulating tumor cells.
Lu SH; Tsai WS; Chang YH; Chou TY; Pang ST; Lin PH; Tsai CM; Chang YC
Cancer Biol Ther; 2016 Apr; 17(4):430-8. PubMed ID: 26828696
[TBL] [Abstract][Full Text] [Related]
28. Tumorigenic potential of circulating prostate tumor cells.
Carvalho FL; Simons BW; Antonarakis ES; Rasheed Z; Douglas N; Villegas D; Matsui W; Berman DM
Oncotarget; 2013 Mar; 4(3):413-21. PubMed ID: 23530114
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of alpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers.
Gumulec J; Masarik M; Krizkova S; Hlavna M; Babula P; Hrabec R; Rovny A; Masarikova M; Sochor J; Adam V; Eckschlager T; Kizek R
Neoplasma; 2012; 59(2):191-201. PubMed ID: 22248277
[TBL] [Abstract][Full Text] [Related]
30. Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer.
Chen J; Cao S; Situ B; Zhong J; Hu Y; Li S; Huang J; Xu J; Wu S; Lin J; Zhao Q; Cai Z; Zheng L; Wang Q
J Exp Clin Cancer Res; 2018 Jun; 37(1):127. PubMed ID: 29954422
[TBL] [Abstract][Full Text] [Related]
31. Heterogeneous PSMA expression on circulating tumor cells: a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer.
Gorges TM; Riethdorf S; von Ahsen O; Nastał Y P; Röck K; Boede M; Peine S; Kuske A; Schmid E; Kneip C; König F; Rudolph M; Pantel K
Oncotarget; 2016 Jun; 7(23):34930-41. PubMed ID: 27145459
[TBL] [Abstract][Full Text] [Related]
32. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
[TBL] [Abstract][Full Text] [Related]
33. Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood.
Jost M; Day JR; Slaughter R; Koreckij TD; Gonzales D; Kinnunen M; Groskopf J; Rittenhouse HG; Vessella RL; Reynolds MA
Mol Cancer; 2010 Jul; 9():174. PubMed ID: 20598135
[TBL] [Abstract][Full Text] [Related]
34. The Novel Association of Circulating Tumor Cells and Circulating Megakaryocytes with Prostate Cancer Prognosis.
Xu L; Mao X; Guo T; Chan PY; Shaw G; Hines J; Stankiewicz E; Wang Y; Oliver RTD; Ahmad AS; Berney D; Shamash J; Lu YJ
Clin Cancer Res; 2017 Sep; 23(17):5112-5122. PubMed ID: 28615267
[No Abstract] [Full Text] [Related]
35. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.
Stott SL; Lee RJ; Nagrath S; Yu M; Miyamoto DT; Ulkus L; Inserra EJ; Ulman M; Springer S; Nakamura Z; Moore AL; Tsukrov DI; Kempner ME; Dahl DM; Wu CL; Iafrate AJ; Smith MR; Tompkins RG; Sequist LV; Toner M; Haber DA; Maheswaran S
Sci Transl Med; 2010 Mar; 2(25):25ra23. PubMed ID: 20424012
[TBL] [Abstract][Full Text] [Related]
36. Copy number variation of urine exfoliated cells by low-coverage whole genome sequencing for diagnosis of prostate adenocarcinoma: a prospective cohort study.
Guan Y; Wang X; Guan K; Wang D; Bi X; Xiao Z; Xiao Z; Shan X; Hu L; Ma J; Li C; Zhang Y; Shou J; Wang B; Qian Z; Xing N
BMC Med Genomics; 2022 May; 15(Suppl 2):104. PubMed ID: 35513884
[TBL] [Abstract][Full Text] [Related]
37. [Significance of the PSA-concentration for the detection of prostate cancer].
Stachon A
Pathologe; 2005 Nov; 26(6):469-72. PubMed ID: 16195861
[TBL] [Abstract][Full Text] [Related]
38. Alpha-methylacyl-CoA racemase and hepsin as urinary prostate cancer markers.
Sroka WD; Adamowski M; Słupski P; Siódmiak J; Jarzemski P; Odrowąż-Sypniewska G; Marszałł MP
Int J Biol Markers; 2015 Nov; 30(4):e401-6. PubMed ID: 25982684
[TBL] [Abstract][Full Text] [Related]
39. Numeric definition of the clinical performance of the nested reverse transcription-PCR for detection of hematogenous epithelial cells and correction for specific mRNA of non-target cell origin as evaluated for prostate cancer cells.
Schamhart D; Swinnen J; Kurth KH; Westerhof A; Kusters R; Borchers H; Sternberg C
Clin Chem; 2003 Sep; 49(9):1458-66. PubMed ID: 12928226
[TBL] [Abstract][Full Text] [Related]
40. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.
Sreekumar A; Laxman B; Rhodes DR; Bhagavathula S; Harwood J; Giacherio D; Ghosh D; Sanda MG; Rubin MA; Chinnaiyan AM
J Natl Cancer Inst; 2004 Jun; 96(11):834-43. PubMed ID: 15173267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
